



February 10, 2026

<b>To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497</b>	<b>To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL</b>
--	---

**Sub: Intimation for Press release of Financial Results for the quarter and Nine Months ended December 31, 2025.**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) we hereby submit the Press release of Financial Results for the quarter and Nine Months ended December 31, 2025.

You are requested to take the above information on your record.

Thanking You.

Yours Faithfully,  
**For ANLON HEALTHCARE LIMITED**

**PUNITKUMAR RASADIA  
MANAGING DIRECTOR  
DIN: 06696258**

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)



## Anlon Healthcare Limited Delivers Blockbuster Q3 FY26 Results with EBITDA up 20x and PAT Turning Strongly Positive; Sustains Robust 9M FY26 Growth

**Rajkot, 09th February 2026** – Anlon Healthcare Limited, one of India’s leading manufacturers of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), announced its **unaudited financial results for Q3 and 9M FY26**, reporting strong growth in revenue, profitability, and margins, supported by robust R&D execution and strategic capacity expansion initiatives.

### Key Financial Highlights:

Particulars (₹ Cr)	Q3 FY25	Q3 FY26	Y-o-Y Change
Total Income	9.38	<b>35.78</b>	<b>↑ 281.47 %</b>
EBITDA	0.60	<b>12.54</b>	<b>↑ 2,006.42%</b>
PAT	(2.49)	<b>5.15</b>	<b>NA</b>
PAT Margins (%)	NA	<b>14.40</b>	<b>NA</b>

Particulars (₹ Cr)	9M FY25	9M FY26	Y-o-Y Change
Total Income	71.49	<b>121.32</b>	<b>↑ 69.71%</b>
EBITDA	15.15	<b>32.56</b>	<b>↑ 114.96%</b>
PAT	3.87	<b>18.02</b>	<b>↑ 365.61 %</b>
PAT Margins (%)	5.41	<b>14.85</b>	<b>↑ 943 BPS</b>

### Key Developments During the Quarter

#### Inorganic Expansion – Transaction Details

- Executed definitive Share Purchase Agreements to acquire a **56.67% equity stake in Bizotic Lifescience** for a total consideration of **₹3.79 crore**, through the purchase of **25.50 lakh equity shares at ₹14.89 per share**.
- Acquired **67.48% equity stake in Apiqo Organics Private Limited** for a total consideration of **₹5.40 crore**, through the acquisition of **55.34 lakh equity shares at ₹9.76 per share**.
- The **acquisition of Apiqo Organics Private Limited has been completed** through an **all-cash transaction**, while the **acquisition of Bizotic Lifescience is pending completion**, subject to the fulfilment of customary closing conditions and regulatory approvals, in line with the agreed transaction timelines.

- **Apiqo Organics Private Limited is currently a subsidiary of Anlon Healthcare Limited, while Bizotic Lifescience is expected to become a subsidiary upon completion of the proposed acquisition, subject to customary approvals.**

#### **Management Commentary:**

**Mr. Punitkumar Rasadia – Chairman & Managing Director of Anlon Healthcare Limited, commented on the company's strong results,**

*" We are pleased to report a strong performance during Q3 and 9M FY26, reflecting the strength of our R&D-led growth strategy, expanding API portfolio, and disciplined execution. During Q3 FY26, the Company recorded Total Income of ₹35.78 crore, representing a YoY growth of 281.5%, with EBITDA at ₹12.54 crore and Profit After Tax of ₹5.15 crore. For the nine-month period ended December 2025, Total Income increased to ₹121.32 crore, up 69.7% YoY, while EBITDA grew by 115.0% to ₹32.56 crore and PAT rose to ₹18.02 crore, resulting in a PAT margin of 14.85%.*

*Beyond strong organic execution, we have taken decisive steps to accelerate our next phase of growth through strategic inorganic initiatives. During the period, we executed **share purchase agreement to acquire a 56.67% controlling stake in Bizotic Lifescience, with the transaction pending, and have successfully completed the acquisition of a 67.48% controlling stake in Apiqo Organics Private Limited, which is now a subsidiary of Anlon Healthcare Limited. Bizotic Lifescience provides a ready-to-operate manufacturing facility, enabling faster scale-up of current portfolio of Intermediate and APIs. Apiqo Organics strengthens our backward integration for pharmaceutical intermediates, improves cost competitiveness, and enhances supply security. Collectively, these acquisitions are expected to expand our consolidated manufacturing capacity to approximately 1,400–1,600 MTPA by FY26, materially strengthening our operational and regulatory capabilities.***

*With these strategic initiatives, combined with a diversified end-market presence across human health, veterinary, nutraceutical, personal care segments and Industrial & Fine Chemicals, we believe Anlon has built a resilient and scalable growth platform. **Backed by organic expansion, inorganic scale-up, and a compliance-hardened manufacturing base, we remain confident of achieving a ~30% revenue CAGR over the next three years, alongside sustainable and gradual improvement in EBITDA margins, while continuing to create long-term value for all stakeholders.***

## About Anlon Healthcare Limited

Incorporated in 2013 and headquartered in Rajkot, Gujarat, *Anlon Healthcare Limited* is a research-driven manufacturer of high-purity advanced pharmaceutical intermediates and APIs that serve as essential building blocks for finished dosage formulations.

The company is among the few Indian manufacturers of **Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol** — key APIs used for pain and inflammation management. Its products cater to multiple sectors, including **pharmaceuticals, nutraceuticals, personal care, and animal health**.

With **400 MTPA installed capacity, four R&D centers and a global presence across 15+ countries**, Anlon continues to advance health through innovation, quality, and sustainability.

## Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

## For Further Information Please Contact

 ConfideLeap Partners	<b>ConfideLeap Partners</b> info@confideleap.com +(91) 85911 45959 www.confideleap.com
--	---